Literature DB >> 34773268

Ethanol attenuates presentation of cytotoxic T-lymphocyte epitopes on hepatocytes of HBV-infected humanized mice.

Murali Ganesan1,2, Weimin Wang3, Saumi Mathews3, Edward Makarov3, Moses New-Aaron1,4, Raghubendra Singh Dagur1,2, Antje Malo5, Ulrike Protzer5,6, Kusum K Kharbanda1,2, Carol A Casey1,2, Larisa Y Poluektova3, Natalia A Osna1,2.   

Abstract

BACKGROUND AND AIMS: Approximately 3.5% of the global population is chronically infected with Hepatitis B Virus (HBV), which puts them at high risk of end-stage liver disease, with the risk of persistent infection potentiated by alcohol consumption. However, the mechanisms underlying the effects of alcohol on HBV persistence remain unclear. Here, we aimed to establish in vivo/ex vivo evidence that alcohol suppresses HBV peptides-major histocompatibility complex (MHC) class I antigen display on primary human hepatocytes (PHH), which diminishes the recognition and clearance of HBV-infected hepatocytes by cytotoxic T-lymphocytes (CTLs).
METHODS: We used fumarylacetoacetate hydrolase (Fah)-/-, Rag2-/-, common cytokine receptor gamma chain knock-out (FRG-KO) humanized mice transplanted with human leukocyte antigen-A2 (HLA-A2)-positive hepatocytes. The mice were HBV-infected and fed control and alcohol diets. Isolated hepatocytes were exposed ex vivo to HBV 18-27-HLA-A2-restricted CTLs to quantify cytotoxicity. For mechanistic studies, we measured proteasome activities, unfolded protein response (UPR), and endoplasmic reticulum (ER) stress in hepatocytes from HBV-infected humanized mouse livers. RESULTS AND
CONCLUSIONS: We found that alcohol feeding attenuated HBV core 18-27-HLA-A2 complex presentation on infected hepatocytes due to the suppression of proteasome function and ER stress induction, which diminished both the processing of HBV peptides and trafficking of HBV-MHC class I complexes to the hepatocyte surface. This alcohol-mediated decrease in MHC class I-restricted antigen presentation of the CTL epitope on target hepatocytes reduced the CTL-specific elimination of infected cells, potentially leading to HBV-infection persistence, which promotes end-stage liver disease outcomes.
© 2021 Research Society on Alcoholism.

Entities:  

Keywords:  EtOH; HBV; antigen presentation; hepatocytes

Mesh:

Substances:

Year:  2021        PMID: 34773268      PMCID: PMC8799491          DOI: 10.1111/acer.14740

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  42 in total

1.  26S proteasomes and immunoproteasomes produce mainly N-extended versions of an antigenic peptide.

Authors:  P Cascio; C Hilton; A F Kisselev; K L Rock; A L Goldberg
Journal:  EMBO J       Date:  2001-05-15       Impact factor: 11.598

2.  Chronic ethanol effects on cellular immune responses to hepatitis B virus envelope protein: an immunologic mechanism for induction of persistent viral infection in alcoholics.

Authors:  M Geissler; A Gesien; J R Wands
Journal:  Hepatology       Date:  1997-09       Impact factor: 17.425

3.  CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection.

Authors:  Robert Thimme; Stefan Wieland; Carola Steiger; John Ghrayeb; Keith A Reimann; Robert H Purcell; Francis V Chisari
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

4.  Tapasin modification on the intracellular epitope HBcAg18-27 enhances HBV-specific CTL immune response and inhibits hepatitis B virus replication in vivo.

Authors:  Xiaohua Chen; Yuyan Tang; Yi Zhang; Meng Zhuo; Zhenghao Tang; Yongsheng Yu; Guoqing Zang
Journal:  Lab Invest       Date:  2014-03-10       Impact factor: 5.662

5.  ATF4 and the integrated stress response are induced by ethanol and cytochrome P450 2E1 in human hepatocytes.

Authors:  Laurent Magne; Etienne Blanc; Beatrice Legrand; Danièle Lucas; Robert Barouki; Hélène Rouach; Michèle Garlatti
Journal:  J Hepatol       Date:  2010-09-29       Impact factor: 25.083

6.  FAT10 suppression stabilizes oxidized proteins in liver cells: Effects of HCV and ethanol.

Authors:  Murali Ganesan; Joseph Hindman; Brittany Tillman; Lee Jaramillo; Larisa I Poluektova; Barbara A French; Kusum K Kharbanda; Samuel W French; Natalia A Osna
Journal:  Exp Mol Pathol       Date:  2015-09-25       Impact factor: 3.362

7.  Robust expansion of human hepatocytes in Fah-/-/Rag2-/-/Il2rg-/- mice.

Authors:  Hisaya Azuma; Nicole Paulk; Aarati Ranade; Craig Dorrell; Muhsen Al-Dhalimy; Ewa Ellis; Stephen Strom; Mark A Kay; Milton Finegold; Markus Grompe
Journal:  Nat Biotechnol       Date:  2007-07-29       Impact factor: 54.908

8.  Spatiotemporal Differences in Presentation of CD8 T Cell Epitopes during Hepatitis B Virus Infection.

Authors:  Atefeh Khakpoor; Yi Ni; Antony Chen; Zi Zong Ho; Vincent Oei; Ninghan Yang; Reshmi Giri; Jia Xin Chow; Anthony T Tan; Patrick T Kennedy; Mala Maini; Stephan Urban; Antonio Bertoletti
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

9.  Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope.

Authors:  A Bertoletti; A Costanzo; F V Chisari; M Levrero; M Artini; A Sette; A Penna; T Giuberti; F Fiaccadori; C Ferrari
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

10.  Interferon-γ induces immunoproteasomes and the presentation of MHC I-associated peptides on human salivary gland cells.

Authors:  Martha E Arellano-Garcia; Kaori Misuno; Simon D Tran; Shen Hu
Journal:  PLoS One       Date:  2014-08-07       Impact factor: 3.240

View more
  1 in total

1.  Cell-to-Cell Communications in Alcohol-Associated Liver Disease.

Authors:  Natalia A Osna; Akiko Eguchi; Ariel E Feldstein; Hidekazu Tsukamoto; Raghubendra S Dagur; Murali Ganesan; Moses New-Aaron; Madan Kumar Arumugam; Srinivas Chava; Marcelle Ribeiro; Gyongyi Szabo; Sebastian Mueller; Shijin Wang; Cheng Chen; Steven A Weinman; Kusum K Kharbanda
Journal:  Front Physiol       Date:  2022-02-21       Impact factor: 4.566

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.